Karyopharm Therapeutics Bankruptcy & Restructuring
Karyopharm Therapeutics Inc. and its subsidiary filed voluntary petitions for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas. The company entered into a Restructuring Support Agreement with 100% of its funded debt holders and Ayrmid Ltd., which will serve as a stalking horse bidder for a merger with the reorganized company. The company will continue operations as a debtor-in-possession while seeking a court-supervised sale or reorganization to maximize stakeholder value.
- Counterparty
- Ayrmid Ltd.